Hydroxychloroquine (HCQ)

DRUG16 trials

Conditions

Advanced AdenocarcinomaAdvanced BRAF Mutant MelanomaBreast CancerCOVID-19COVID-19 PreventionCOVID19Cicatricial AlopeciaCovid19

Phase 1

A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer

CompletedNCT01506973

Abramson Cancer Center at Penn MedicineAdvanced Adenocarcinoma, Metastatic Adenocarcinoma

Start: 2011-12-31End: 2022-03-31Updated: 2025-07-25

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

CompletedNCT01897116

Abramson Cancer Center at Penn MedicineMelanoma

Start: 2013-06-30End: 2016-10-05Updated: 2020-05-29

Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

CompletedNCT02257424

Abramson Cancer Center at Penn MedicineAdvanced BRAF Mutant Melanoma

Start: 2014-10-31End: 2021-10-31Updated: 2022-01-20

Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (GLACIER)

WithdrawnNCT03400254

Abramson Cancer Center at Penn MedicineBreast Cancer

Start: 2019-02-26End: 2019-11-12Updated: 2020-04-28

Phase 2

Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss

WithdrawnNCT02379650

University of UtahMiscarriage, Recurrent Pregnancy Loss

Start: 2016-07-31End: 2021-07-31Updated: 2016-08-12

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

CompletedNCT03037437

The University of Texas Health Science Center at San AntonioHepatocellular Cancer

Start: 2017-02-16End: 2025-06-27Updated: 2025-09-04

COVID-19 PrEP HCW HCQ Study

CompletedNCT04354870

NYU Langone HealthCOVID-19

Start: 2020-04-03End: 2020-10-01Updated: 2022-12-14

Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

TerminatedNCT04358068

National Institute of Allergy and Infectious Diseases (NIAID)COVID-19, SARS-CoV 2

Start: 2020-05-13End: 2020-07-08Updated: 2021-11-16

Treating COVID-19 With Hydroxychloroquine (TEACH)

TerminatedNCT04369742

NYU Langone HealthCOVID-19

Start: 2020-04-15End: 2021-04-01Updated: 2022-04-22

A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease

Not yet recruitingNCT06816810

Ottawa Hospital Research InstituteParkinson&Amp;#39;s Disease

Start: 2025-03-31End: 2027-03-31Target: 40Updated: 2025-02-10

Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome

Not yet recruitingNCT06862284

Peking University People's HospitalPrimary Sjögren's Syndrome (pSS)

Start: 2025-03-10End: 2027-08-31Target: 30Updated: 2025-03-11

Phase 3

Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals

WithdrawnNCT04349228

Abderrahmane Mami HospitalCOVID19, Healthcare Worker, Hydroxychloroquine +2

Start: 2020-04-28End: 2020-07-15Updated: 2020-08-28

Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients

TerminatedNCT04522466

Centre Hospitalier Universitaire de Saint EtienneSars-CoV2

Start: 2020-04-03End: 2020-05-28Updated: 2020-09-07

Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19

NCT04858633

Post Graduate Institute of Medical Education and Research, ChandigarhCovid19, COVID-19 Prevention

Start: 2021-03-22End: 2021-06-30Target: 1000Updated: 2021-06-11

Unknown Phase

Inducing Immune Quiescence to Prevent HIV Infection in Women

CompletedNCT02079077

University of ManitobaHIV

Start: 2014-04-30End: 2018-01-01Updated: 2019-10-10

The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)

Not yet recruitingNCT07190534

Erasmus Medical CenterCicatricial Alopecia, Frontal Fibrosing Alopecia

Start: 2025-11-30End: 2027-05-31Target: 50Updated: 2025-09-29

Journal of Clinical Oncology2025-01-27

Hydroxychloroquine Pre-Exposure Prophylaxis to Prevent SARS-CoV-2 Among Health Care Workers at High Risk For SARS-CoV-2 Exposure: A Nonrandomized Controlled Trial

Infectious Diseases Diagnosis & Treatment2022-11-18

Low-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention

Frontiers in Immunology2021-11-1811 citations

Phase II study of modulation of sorafenib (SOR)-induced autophagy using hydroxychloroquine (HCQ) in advanced hepatocellular cancer (HCC): Planned interim efficacy and safety analysis.

Journal of Clinical Oncology2021-01-204 citations

Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer

JAMA Oncology2019-05-23276 citations

Preventing HIV infection without targeting the virus: how reducing HIV target cells at the genital tract is a new approach to HIV prevention.

2017-09-1215 citations

Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma.

Journal of Clinical Oncology2015-05-208 citations